GW Pharma appears poised to enter the United States cannabis market.
The British company reportedly could get clearance from the U.S. Food and Drug Administration for a CBD-based product by early next year.
The drug, called Epidiolex, previously received fast-track status from the FDA and is now in the final Phase 3 study for pediatric epilepsy disorders, according to the Huffington Post. Results are expected in the first quarter of next year.
Epidiolex is expected to “breeze through this final stage,” and it could be on the market in the first half of 2016, the site reported.
Since Epidiolex is derived from marijuana, GW Pharmaceuticals will likely have to invest in infrastructure to grow cannabis in the United States rather than ship the product over from the U.K. It would then have to manufacture the drug in whichever states it wants to sell Epidiolex in.
